Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial of Epirubicin and Cyclophosphamide Followed by Docetaxel Against Docetaxel and Cyclophosphamide in Patients With TOP2A Normal Early Breast Cancer

NCT00689156 is registered in ClinicalTrials.gov with Danish Breast Cancer Cooperative Group as lead sponsor.

NCT NCT00689156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00689156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial of Epirubicin and Cyclophosphamide Followed by Docetaxel Against Docetaxel and Cyclophosphamide in Patients With TOP2A Normal Early Breast Cancer
Lead sponsor
Danish Breast Cancer Cooperative Group
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2008
Completion date
January 31, 2013
Enrollment
2,015 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms